Diarylalkane compounds for use in anti-aging, wrinkle reduction, and extracellular matrix-boosting topical skincare are disclosed. Data and information from clinical trials that demonstrated reduced numbers of fine lines and wrinkles, reduced wrinkle depth, and reduced skin roughness upon treatment with the compound are also disclosed.

The present invention is in the field of antioxidants and relates to cosmetic or pharmaceutical, preferably dermatological, compositions or homecare product comprising or consisting of a synergistic combination of a specific antioxidant and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or homecare product, in particular for scavenging reactive oxygen species (ROS), for inhibition matrix metalloproteinases expression and/or for inhibiting interleukin 8 (IL-8) secretion. Additionally, the present invention relates to the use of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols for enhancing the antioxidative effect of an antioxidant in a cosmetic or pharmaceutical, preferably dermatological, composition or homecare product, and/or for enhancing the antioxidative effect of a cosmetic or pharmaceutical, preferably dermatological, composition upon application.

A method for treating skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Chamaecrista mimosoides, wherein the composition reduces tyrosinase activity in the skin, increases antioxidant activity in the skin, and/or increases skin moisture content.

A method of treating a person's skin is disclosed. The method can include topically applying to the skin a composition that includes an extract of Opuntia ficus-indica, water, caprylic/capric triglyceride, glycerin, Butyrospermum parkii (shea) butter, ammonium acryloyldimethyltaurate/vp copolymer, butylene glycol, ethylhexylglycerin, tocopherol or tocopheryl acetate, disodium EDTA, sodium hydroxide, caprylyl glycol, and Helianthus annuus (sunflower) seed oil.

The invention provides topical formulations and methods comprising charged bioactive agents complexed with amphipol polymers for dermal and transdermal delivery, optionally further including TJ-modulating peptides.

The invention provides topical formulations and methods comprising charged bioactive agents complexed with amphipol polymers for dermal and transdermal delivery, optionally further including TJ-modulating peptides.

Provided in the present disclosure is a composition comprising hydroquinone or a derivative thereof as an active ingredient, and characterized in that the hydroquinone or the derivative thereof is stabilized by means of poloxamer. The composition of the present disclosure increases the soluble concentration of the hydroquinone or the derivative thereof, can have high melt stability without precipitation even at high concentration in water, can enhance storage stability by preventing oxidation reaction to external stimulations such as heat, oxygen and light, can prevent discoloration, and thus has reduced toxicity induced by an oxidation product of the hydroquinone and can reduce inflammatory response. Also, the composition of the present disclosure can enhance whitening efficacy by enhancing the skin permeability of the hydroquinone or the derivative thereof by means of micelles, and thus is useful for a whitening activity having hydroquinone or a derivative thereof as an active ingredient.

A topical skin composition is disclosed. The topical skin composition can include a Bougainvillea glabra extract, hyaluronic acid, glycerin, tocopherol, phenoxyethanol, sodium hydroxide, and ethylhexylglycerin.

A method for treating skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Bougainvillea glabra, wherein the composition reduces tyrosinase activity or melanin production in the skin.

The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.